Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, announces a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services. At closing, PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest’s AI and digital R&D and solutions center, supporting Quest’s specialty pathology businesses, AmeriPath and Dermpath Diagnostics.

Read the full article: Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis //

Source: https://www.prnewswire.com/news-releases/quest-diagnostics-to-acquire-pathai-diagnostics-to-accelerate-ai-and-digital-pathology-adoption-in-cancer-diagnosis-forms-licensing-agreements-with-pathai-302132353.html

Leave a Comment

Your email address will not be published.

Scroll to Top